drugset / Trial / NCT00990912
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the long term safety of patients with refractory solid tumors who have experienced clinical benefit after at least 6 cycles of treatment in BMS Protocol CA124-001 or CA124-002.
Timeline
- Start
- 2004-01
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Comparator | Irinotecan | Small molecule | 9 mg/m2 | Intravenous |
| Comparator | Irinotecan | Small molecule | 10 mg/m2 | Intravenous |
| Comparator | Irinotecan | Small molecule | 12 mg/m2 | Intravenous |
| Comparator | Irinotecan | Small molecule | 18 mg/m2 | Intravenous |